Clinical chemistry · 2026
Copy-Number Profiling and Methylation-Based Tumor Typing during Prenatal Cell-Free DNA Screening.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tuveri Stefania, Jatsenko Tatjana, Sudhakaran Dhanya, Fu Qiang, Passemiers Antoine, Pagliazzi Angelica, Van Den Bogaert Kris, Vancoillie Leen, Parijs Ilse, Brison Nathalie, Van Calsteren Kristel, Lejeune Charlotte, Naesens Maarten, Vandenberghe Peter, Amant Frédéric, Lenaerts Liesbeth, Vermeesch Joris R
Аннотация
BACKGROUND: Prenatal cell-free DNA (cfDNA) screening is primarily designed to detect fetal chromosomal abnormalities, but can also identify aneuploidies derived from other tissues, including cancer. The identification of aneuploidies of unknown origin during prenatal cfDNA screening can lead to time-consuming multistage investigations and anxiety for the expecting mother.
METHODS: To expedite the identification of the origin of copy-number aberrations and guide clinical management of such profiles suggestive of maternal malignancy, we developed a methylation and aneuploidy-aware prenatal screening pipeline. Plasma cfDNA is enzymatically converted to identify the methylated cytosines during sequencing. The tissue of origin is predicted by leveraging a cell-type-specific methylome atlas into our methylation-based deconvolution algorithm, MetDecode.
RESULTS: We demonstrate that aneuploidy profiling on enzymatically converted cfDNA enables the identification of placental and cancer-derived aneuploidies with similar accuracy compared with conventional prenatal cfDNA screening. The methylation-based deconvolution pinpointed the tumor origin correctly in 91.67% of the pregnant women with a tumor fraction >3%.
CONCLUSION: Methylome and aneuploidy-aware cfDNA screening could substantially improve the diagnostic processes, pinpoint the origins of aneuploidy and improve cancer management during pregnancy.
METHODS: To expedite the identification of the origin of copy-number aberrations and guide clinical management of such profiles suggestive of maternal malignancy, we developed a methylation and aneuploidy-aware prenatal screening pipeline. Plasma cfDNA is enzymatically converted to identify the methylated cytosines during sequencing. The tissue of origin is predicted by leveraging a cell-type-specific methylome atlas into our methylation-based deconvolution algorithm, MetDecode.
RESULTS: We demonstrate that aneuploidy profiling on enzymatically converted cfDNA enables the identification of placental and cancer-derived aneuploidies with similar accuracy compared with conventional prenatal cfDNA screening. The methylation-based deconvolution pinpointed the tumor origin correctly in 91.67% of the pregnant women with a tumor fraction >3%.
CONCLUSION: Methylome and aneuploidy-aware cfDNA screening could substantially improve the diagnostic processes, pinpoint the origins of aneuploidy and improve cancer management during pregnancy.